{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:23:12Z","timestamp":1783686192469,"version":"3.55.0"},"reference-count":19,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Yellow fever vaccination is recommended for travelers visiting endemic regions in South America and Africa. The live-attenuated vaccine (Stamaril\u00ae, Sanofi Pasteur) is produced in embryonated chicken eggs and contains residual ovalbumin, posing a challenge for individuals with egg protein allergy. Case Presentation: We report the case of a 35-year-old male disaster relief worker with confirmed egg protein allergy and moderate sensitization but no history of anaphylaxis. Under normal circumstances, a statement confirming that vaccination is not possible would be sufficient for entry. However, due to his work-related duties and the relevant guidelines from his employer, there was an urgent need for vaccination despite his egg protein allergy. A comprehensive allergy work-up including skin prick testing, serum-specific IgE, and oral provocation testing revealed a moderate allergy without systemic reactions. Intervention: Following informed consent and risk assessment, a fractional dose (0.1 mL) of the reconstituted yellow fever vaccine was administered under close monitoring. The patient developed a localized dermal reaction without systemic symptoms. Post-vaccination neutralization testing confirmed seroconversion indicating protective immunity. Discussion: Although yellow fever vaccination is considered contraindicated in individuals with severe egg protein allergy, the literature supports its cautious use in selected cases. Fractional dosing has emerged as an effective dose-sparing strategy. Studies show that even in egg protein-allergic individuals, adverse events are rare. Conclusions: In this case, a fractional yellow fever vaccination was safe and an effective option for an egg-allergic individual in a high-risk occupational setting, supporting a personalized approach based on clinical risk assessment and current evidence.<\/jats:p>","DOI":"10.3390\/vaccines14070606","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:43:34Z","timestamp":1783683814000},"page":"606","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yellow Fever Vaccination in an Individual with Confirmed Egg Protein Allergy: A Case Report"],"prefix":"10.3390","volume":"14","author":[{"given":"Nelly","family":"Otte","sequence":"first","affiliation":[{"name":"Institute of Occupational, Social and Environmental Medicine, Medical Faculty, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Medical Faculty, Ruhr University Bochum, 44789 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Maleki","family":"Kahaki","sequence":"additional","affiliation":[{"name":"Institute of Occupational, Social and Environmental Medicine, Medical Faculty, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Aachen Comprehensive Allergy Center (ACAC), University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Wurpts","sequence":"additional","affiliation":[{"name":"Aachen Comprehensive Allergy Center (ACAC), University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Department of Dermatology and Allergology, Medical Faculty, University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kraus","sequence":"additional","affiliation":[{"name":"Institute of Occupational, Social and Environmental Medicine, Medical Faculty, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Aachen Comprehensive Allergy Center (ACAC), University Hospital RWTH Aachen, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-9783","authenticated-orcid":false,"given":"Julia","family":"Krabbe","sequence":"additional","affiliation":[{"name":"Institute of Occupational, Social and Environmental Medicine, Medical Faculty, University Hospital RWTH Aachen, 52074 Aachen, Germany"},{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Medical Faculty, Ruhr University Bochum, 44789 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","unstructured":"(2026, April 15). Yellow Fever. Available online: https:\/\/www.afro.who.int\/health-topics\/yellow-fever."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1086\/344180","article-title":"A Belgian traveler who acquired yellow fever in the Gambia","volume":"35","author":"Colebunders","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","unstructured":"(2026, April 15). International Health Regulations 2005. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/246107\/9789241580496-eng.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","article-title":"Anaphylaxis from yellow fever vaccine","volume":"103","author":"Kelso","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: A systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"taz024","DOI":"10.1093\/jtm\/taz024","article-title":"Fractional-dose yellow fever vaccination: An expert review","volume":"26","author":"Roukens","year":"2019","journal-title":"J. Travel Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine","volume":"9","author":"Martins","year":"2013","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"taad154","DOI":"10.1093\/jtm\/taad154","article-title":"Incidence of anaphylaxis to YF-VAX\u00ae yellow fever vaccination: A retrospective evaluation of vaccine adverse event reports 1999\u20132018","volume":"31","author":"McClenathan","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_10","unstructured":"CDC (2025). Yellow Book."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.46747\/cfp.700110","article-title":"Vaccination and egg allergy","volume":"70","author":"Abrams","year":"2024","journal-title":"Can. Fam. Physician"},{"key":"ref_12","first-page":"52","article-title":"No yellow fever vaccine reactions in IgE-mediated egg allergic patients","volume":"186","author":"Calle","year":"2024","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15586\/aei.v51i4.850","article-title":"Frequency of allergic reactions in egg allergic patients after receiving the yellow fever vaccine","volume":"51","author":"Aparicio","year":"2023","journal-title":"Allergol. Immunopathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.jacig.2023.100089","article-title":"Safe administration of yellow fever vaccine in patients with suspected egg allergy","volume":"2","author":"Abrantes","year":"2023","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_15","unstructured":"WHO (2026, June 12). Lower Doses of Yellow Fever Vaccine Could Be Used in Emergencies. Published 17 June 2016, Available online: https:\/\/www.who.int\/news\/item\/17-06-2016--lower-doses-of-yellow-fever-vaccine-could-be-used-in-emergencies."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Campi-Azevedo, A.C., Reis, L.R., Peruhype-Magalh\u00e3es, V., Coelho-dos-Reis, J.G., Antonelli, L.R., Fonseca, C.T., Costa-Pereira, C., Souza-Fagundes, E.M., Costa-Rocha, I.A.D., and Mambrini, J.V.D.M. (2019). Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02192"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1590\/s1678-9946201759002","article-title":"Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults","volume":"59","author":"Miyaji","year":"2017","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/trstmh\/trag026","article-title":"A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults","volume":"120","author":"Saucha","year":"2026","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"taaf106","DOI":"10.1093\/jtm\/taaf106","article-title":"Is a second dose of yellow fever vaccine needed? A systematic review of humoral and cell-mediated immunity after revaccination","volume":"32","author":"Ferrara","year":"2025","journal-title":"J. Travel Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/606\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:01:46Z","timestamp":1783684906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070606"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070606","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}